Piper Jaffray Cos. set a $96.00 price target on Neurocrine Biosciences Inc. (NASDAQ:NBIX) in a research report released on Tuesday. The firm currently has a a buy rating on the stock.

NBIX has been the topic of a number of other research reports. Jefferies Group reaffirmed a buy rating and set a $61.00 price target on shares of Neurocrine Biosciences in a report on Friday, September 23rd. Robert W. Baird reaffirmed an outperform rating and set a $66.00 price target on shares of Neurocrine Biosciences in a report on Tuesday, August 30th. Leerink Swann assumed coverage on shares of Neurocrine Biosciences in a research note on Tuesday, October 4th. They issued an outperform rating and a $70.00 price objective on the stock. BMO Capital Markets reiterated an outperform rating and issued a $66.00 price objective on shares of Neurocrine Biosciences in a research note on Friday, September 23rd. Finally, HC Wainwright reiterated a buy rating on shares of Neurocrine Biosciences in a research note on Friday, August 5th. One analyst has rated the stock with a sell rating and ten have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average price target of $65.50.

Shares of Neurocrine Biosciences (NASDAQ:NBIX) opened at 45.00 on Tuesday. The stock’s 50 day moving average is $50.71 and its 200 day moving average is $47.63. Neurocrine Biosciences has a 52-week low of $31.25 and a 52-week high of $58.46. The firm’s market capitalization is $3.90 billion.

In other news, insider Malcolm Lloyd-Smith sold 9,000 shares of Neurocrine Biosciences stock in a transaction on Thursday, September 1st. The stock was sold at an average price of $50.00, for a total transaction of $450,000.00. Following the completion of the sale, the insider now directly owns 9,000 shares in the company, valued at $450,000. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Corinne H. Nevinny sold 5,000 shares of Neurocrine Biosciences stock in a transaction on Monday, August 8th. The stock was sold at an average price of $48.54, for a total value of $242,700.00. Following the sale, the director now owns 25,555 shares of the company’s stock, valued at $1,240,439.70. The disclosure for this sale can be found here. Insiders own 4.80% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. Alliancebernstein L.P. increased its stake in Neurocrine Biosciences by 650.2% in the second quarter. Alliancebernstein L.P. now owns 1,104,515 shares of the company’s stock valued at $50,200,000 after buying an additional 957,289 shares during the last quarter. Senator Investment Group LP purchased a new stake in Neurocrine Biosciences during the second quarter valued at $38,632,000. American Century Companies Inc. increased its stake in Neurocrine Biosciences by 890.6% in the second quarter. American Century Companies Inc. now owns 821,527 shares of the company’s stock valued at $37,338,000 after buying an additional 738,598 shares during the last quarter. Pictet Asset Management Ltd. increased its stake in Neurocrine Biosciences by 267.2% in the second quarter. Pictet Asset Management Ltd. now owns 705,229 shares of the company’s stock valued at $35,015,000 after buying an additional 513,172 shares during the last quarter. Finally, State Street Corp increased its stake in Neurocrine Biosciences by 22.9% in the first quarter. State Street Corp now owns 2,682,064 shares of the company’s stock valued at $106,077,000 after buying an additional 499,687 shares during the last quarter. Institutional investors and hedge funds own 96.70% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is engaged in the development of pharmaceutical products focused on neurological and endocrine-based diseases and disorders. The Company’s two lead late-stage clinical programs are Elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc (AbbVie), and NBI-98854 (valbenazine), a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders.

5 Day Chart for NASDAQ:NBIX

Receive News & Stock Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related stocks with our FREE daily email newsletter.